Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Melanoma 1Leukemia, Promyelocytic, Acute 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

Arsenic Trioxide 21Tretinoin 20Cytarabine 12Cyclophosphamide 11Busulfan 10Methotrexate 9Idarubicin 9Filgrastim 8fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 6Tacrolimus 5Gemtuzumab 5Etoposide 5Radiotherapy 4Clofarabine 4Antilymphocyte Serum 4Topotecan 3Mycophenolic Acid 3Mitoxantrone 3Mercaptopurine 3Daunorubicin 3venetoclax 2lintuzumab 2Whole-Body Irradiation 2Thiotepa 2Sorafenib 2Granulocyte Colony-Stimulating Factor 2Cyclosporins 2Cyclosporine 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Promyelocytic, Acute × arsenous acid × Clear all
NCT01409161 2026-05-20

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
151 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡